.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
US Department of Justice
Johnson and Johnson
Baxter
Fuji
Medtronic
Chinese Patent Office
UBS
Federal Trade Commission
Colorcon

Generated: November 19, 2017

DrugPatentWatch Database Preview

Recro Gainesville Company Profile

« Back to Dashboard

What is the competitive landscape for RECRO GAINESVILLE, and what generic and branded alternatives to RECRO GAINESVILLE drugs are available?

RECRO GAINESVILLE has two approved drugs.



Summary for Recro Gainesville

US Patents:0
Tradenames:2
Ingredients:1
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-004May 10, 1996RXYesYes► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-003Jan 9, 1992ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-002May 29, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-001May 29, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Recro Gainesville

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-001May 29, 1990► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-004May 10, 1996► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-002May 29, 1990► Subscribe► Subscribe
Recro Gainesville
VERELAN
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019614-003Jan 9, 1992► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for RECRO GAINESVILLE drugs

Drugname Dosage Strength Tradename Submissiondate
verapamil hydrochloride
Extended-release Tablets100 mg and 200 mg
VERELAN PM
7/20/2006
verapamil hydrochloride
Extended-release Tablets300 mg
VERELAN PM
5/19/2006

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Queensland Health
Deloitte
Daiichi Sankyo
Cerilliant
Healthtrust
Merck
Colorcon
Covington
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot